[
  {
    "id": "fc_tb_treatment_1117f351",
    "front": "IPA: primary risk factor?",
    "back": "Immunocompromised: neutropenia, HSCT, high steroids, organ transplant.",
    "difficulty": "easy",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Pulmonary Tuberculosis - Treatment Regimens",
    "bookId": "tb_treatment",
    "sourceSection": null,
    "sourceLocation": {
      "bookName": "30.TUBERCULOSIS INTEGRATED SESSION 2 (1)",
      "chapter": "NEW REGIMENS",
      "section": null,
      "pageNumber": 434
    }
  },
  {
    "id": "fc_tb_treatment_fdd22962",
    "front": "IPA: first-line antifungal?",
    "back": "Voriconazole. Others: Isavuconazole, Liposomal Amphotericin B.",
    "difficulty": "easy",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Pulmonary Tuberculosis - Treatment Regimens",
    "bookId": "tb_treatment",
    "sourceSection": null,
    "sourceLocation": {
      "bookName": "30.TUBERCULOSIS INTEGRATED SESSION 2 (1)",
      "chapter": "NEW REGIMENS",
      "section": null,
      "pageNumber": 434
    }
  },
  {
    "id": "fc_tb_treatment_d494cb62",
    "front": "Long COVID: key features?",
    "back": "Long-term tissue damage, unresolved inflammation.",
    "difficulty": "easy",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Pulmonary Tuberculosis - Treatment Regimens",
    "bookId": "tb_treatment",
    "sourceSection": null,
    "sourceLocation": {
      "bookName": "30.TUBERCULOSIS INTEGRATED SESSION 2 (1)",
      "chapter": "NEW REGIMENS",
      "section": null,
      "pageNumber": 434
    }
  },
  {
    "id": "fc_tb_treatment_5254e992",
    "front": "Long COVID: pulmonary symptoms?",
    "back": "Dyspnea, cough.",
    "difficulty": "easy",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Pulmonary Tuberculosis - Treatment Regimens",
    "bookId": "tb_treatment",
    "sourceSection": null,
    "sourceLocation": {
      "bookName": "30.TUBERCULOSIS INTEGRATED SESSION 2 (1)",
      "chapter": "NEW REGIMENS",
      "section": null,
      "pageNumber": 434
    }
  },
  {
    "id": "fc_tb_treatment_5ae60585",
    "front": "Long COVID: cardiac symptoms?",
    "back": "Chest pain, palpitations, tachycardia.",
    "difficulty": "easy",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Pulmonary Tuberculosis - Treatment Regimens",
    "bookId": "tb_treatment",
    "sourceSection": null,
    "sourceLocation": {
      "bookName": "30.TUBERCULOSIS INTEGRATED SESSION 2 (1)",
      "chapter": "NEW REGIMENS",
      "section": null,
      "pageNumber": 434
    }
  },
  {
    "id": "fc_tb_treatment_356e9d7e",
    "front": "Long COVID: neurological symptoms?",
    "back": "Cognitive impairment, fatigue, headache, depression, insomnia.",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Pulmonary Tuberculosis - Treatment Regimens",
    "bookId": "tb_treatment",
    "sourceSection": null,
    "sourceLocation": {
      "bookName": "30.TUBERCULOSIS INTEGRATED SESSION 2 (1)",
      "chapter": "NEW REGIMENS",
      "section": null,
      "pageNumber": 434
    }
  },
  {
    "id": "fc_tb_treatment_7f1f74a8",
    "front": "Rajpal study: athletes post-COVID CMR?",
    "back": "15% myocarditis findings (T2 signal, LGE).",
    "difficulty": "hard",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Pulmonary Tuberculosis - Treatment Regimens",
    "bookId": "tb_treatment",
    "sourceSection": null,
    "sourceLocation": {
      "bookName": "30.TUBERCULOSIS INTEGRATED SESSION 2 (1)",
      "chapter": "NEW REGIMENS",
      "section": null,
      "pageNumber": 434
    }
  },
  {
    "id": "fc_tb_treatment_2739574a",
    "front": "Long COVID core pathology?",
    "back": "Tissue damage, unresolved inflammation.",
    "difficulty": "easy",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Pulmonary Tuberculosis - Treatment Regimens",
    "bookId": "tb_treatment",
    "sourceSection": null,
    "sourceLocation": {
      "bookName": "30.TUBERCULOSIS INTEGRATED SESSION 2 (1)",
      "chapter": "NEW REGIMENS",
      "section": null,
      "pageNumber": 434
    }
  },
  {
    "id": "fc_tb_treatment_b7973f00",
    "front": "Long COVID common pulmonary symptoms?",
    "back": "Dyspnea, cough.",
    "difficulty": "easy",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Pulmonary Tuberculosis - Treatment Regimens",
    "bookId": "tb_treatment",
    "sourceSection": null,
    "sourceLocation": {
      "bookName": "30.TUBERCULOSIS INTEGRATED SESSION 2 (1)",
      "chapter": "NEW REGIMENS",
      "section": null,
      "pageNumber": 434
    }
  },
  {
    "id": "fc_tb_treatment_0c8cb7a5",
    "front": "Long COVID pulmonary damage mechanisms?",
    "back": "Fibrosis, pulmonary thrombus, cough hypersensitivity.",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Pulmonary Tuberculosis - Treatment Regimens",
    "bookId": "tb_treatment",
    "sourceSection": null,
    "sourceLocation": {
      "bookName": "30.TUBERCULOSIS INTEGRATED SESSION 2 (1)",
      "chapter": "NEW REGIMENS",
      "section": null,
      "pageNumber": 434
    }
  },
  {
    "id": "fc_tb_treatment_435a59f5",
    "front": "Long COVID common neurological symptoms?",
    "back": "Cognitive impairment, fatigue, headache, depression, insomnia.",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Pulmonary Tuberculosis - Treatment Regimens",
    "bookId": "tb_treatment",
    "sourceSection": null,
    "sourceLocation": {
      "bookName": "30.TUBERCULOSIS INTEGRATED SESSION 2 (1)",
      "chapter": "NEW REGIMENS",
      "section": null,
      "pageNumber": 434
    }
  },
  {
    "id": "fc_tb_treatment_7b763aa3",
    "front": "Long COVID \"other\" symptoms include?",
    "back": "Fatigue, joint pain, myalgia, orthostatic intolerance, autonomic dysfunction.",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Pulmonary Tuberculosis - Treatment Regimens",
    "bookId": "tb_treatment",
    "sourceSection": null,
    "sourceLocation": {
      "bookName": "30.TUBERCULOSIS INTEGRATED SESSION 2 (1)",
      "chapter": "NEW REGIMENS",
      "section": null,
      "pageNumber": 434
    }
  },
  {
    "id": "fc_tb_treatment_f8934a58",
    "front": "Long COVID pathophysiology?",
    "back": "Long-term tissue damage + unresolved inflammation.",
    "difficulty": "easy",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Pulmonary Tuberculosis - Treatment Regimens",
    "bookId": "tb_treatment",
    "sourceSection": null,
    "sourceLocation": {
      "bookName": "30.TUBERCULOSIS INTEGRATED SESSION 2 (1)",
      "chapter": "NEW REGIMENS",
      "section": null,
      "pageNumber": 434
    }
  },
  {
    "id": "fc_tb_treatment_abc3a0b6",
    "front": "IPF PH classification group?",
    "back": "Group 3 PH (CLD-PH)",
    "difficulty": "easy",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Pulmonary Tuberculosis - Treatment Regimens",
    "bookId": "tb_treatment",
    "sourceSection": null,
    "sourceLocation": {
      "bookName": "30.TUBERCULOSIS INTEGRATED SESSION 2 (1)",
      "chapter": "NEW REGIMENS",
      "section": null,
      "pageNumber": 434
    }
  },
  {
    "id": "fc_tb_treatment_3e8252aa",
    "front": "IPF: Angiotensin II inhibitors effect?",
    "back": "Lower PVR; beneficial in CLD-PH.",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Pulmonary Tuberculosis - Treatment Regimens",
    "bookId": "tb_treatment",
    "sourceSection": null,
    "sourceLocation": {
      "bookName": "30.TUBERCULOSIS INTEGRATED SESSION 2 (1)",
      "chapter": "NEW REGIMENS",
      "section": null,
      "pageNumber": 434
    }
  },
  {
    "id": "fc_tb_treatment_b8638791",
    "front": "CLD-PH (e.g., IPF) main treatment?",
    "back": "Optimal lung disease management, hypoxemia correction, transplant.",
    "difficulty": "easy",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Pulmonary Tuberculosis - Treatment Regimens",
    "bookId": "tb_treatment",
    "sourceSection": null,
    "sourceLocation": {
      "bookName": "30.TUBERCULOSIS INTEGRATED SESSION 2 (1)",
      "chapter": "NEW REGIMENS",
      "section": null,
      "pageNumber": 434
    }
  },
  {
    "id": "fc_tb_treatment_8f076eec",
    "front": "IPF CT: main PA diameter PH marker?",
    "back": "Failed to differentiate PH presence.",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Pulmonary Tuberculosis - Treatment Regimens",
    "bookId": "tb_treatment",
    "sourceSection": null,
    "sourceLocation": {
      "bookName": "30.TUBERCULOSIS INTEGRATED SESSION 2 (1)",
      "chapter": "NEW REGIMENS",
      "section": null,
      "pageNumber": 434
    }
  },
  {
    "id": "fc_tb_treatment_394a54d4",
    "front": "ACE inhibitors role in CLD-PH (IPF)?",
    "back": "Studies have not clarified a role.",
    "difficulty": "moderate",
    "cardType": "definition",
    "conceptTags": [],
    "topic": "Pulmonary Tuberculosis - Treatment Regimens",
    "bookId": "tb_treatment",
    "sourceSection": null,
    "sourceLocation": {
      "bookName": "30.TUBERCULOSIS INTEGRATED SESSION 2 (1)",
      "chapter": "NEW REGIMENS",
      "section": null,
      "pageNumber": 434
    }
  }
]